February 2, 2021 11:29 AM EST

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

James Sabry and Aviv Regev at Roche and Genentech have been racking up early stage partnerships, tying up with early stage biotechs developing everything from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Can Bill Anderson save Bayer?

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

CDC is investigating five hospitalizations after use of Valneva’s chikungunya vaccine

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

How AI can address ongoing challenges in the life sciences industry

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6